Published Date: 28-Jul-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Intravenous Immunoglobulin Market size is expected to reach $17.3 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.
The Hospital Pharmacy market dominated the Global Intravenous Immunoglobulin Market by Distribution Channel in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $9.03 billion by 2028. This is due to the wide network of hospitals and the convenient selection of items that are easily accessible through hospital pharmacies. Also, the rising prevalence of primary immunological deficiencies, hepatitis C, and other disorders has resulted in an increase in hospitalizations around the world, increasing customer preference for hospital pharmacies.
The Hypogammaglobulinemia market is expected to witness a CAGR of 7.3% during (2022 - 2028). This is due to the rising prevalence of primary immunodeficiency disorders (PID) over the world. In patients with lymphoproliferative diseases, it is the most frequent chronic immunological deficiency (LPDs).
North America is the fastest growing region in the Global Intravenous Immunoglobulin Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $7.51 billion by 2028. The Europe market is estimated to witness a CAGR of 6.4% during (2022 - 2028). Additionally, The Asia Pacific market would experience a CAGR of 7.8% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Grifols, S.A., Takeda Pharmaceutical Company Limited, Baxter International, Inc., Biotest AG (Tiancheng International Investment Limited), LFB S.A., CSL Limited (CSL Behring), Octapharma AG, Kedrion S.p.A, and Bayer AG.
By Distribution Channel
Unique Offerings from KBV Research